Brainstorm Cell Therapeutics (BCLI)
(Delayed Data from NSDQ)
$0.47 USD
+0.03 (6.09%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.50 +0.03 (6.38%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BCLI 0.47 +0.03(6.09%)
Will BCLI be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BCLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCLI
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
BCLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCLI
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
BrainStorm Cell Therapeutics GAAP EPS of -$0.05 beats by $0.02
BCLI Stock Earnings: Brainstorm Cell Reported Results for Q1 2024